Central Region, Central, Singapore In 2014 was created Esco Ventures, which is appeared as VC. Esco Ventures appeared to be a CVC structure as part of the corporation.
Among the most popular portfolio startups of the fund, we may highlight Carmentix Pte Ltd.. We can highlight the next thriving fund investment areas, such as Health Care, Health Diagnostics.
The fund was created by XiangQian (XQ) Lin.
The fund is constantly included in less than 2 investment rounds annually. The top activity for fund was in 2015. The common things for fund are deals in the range of 1 - 5 millions dollars.
The standard case for the fund is to invest in rounds with 1 partaker. In the next rounds fund is usually obtained by Sands Capital Ventures, PBM Capital Group, Northpond Ventures.
Funds with similar focus
| Fund Name | Location |
| Aiche Technology | Beijing, Beijing, China |
| Beijing Chengchuang Lihe Angel Investment Company | Beijing, Beijing, China |
| Capital Southwest Corporation | Dallas, Texas, United States |
| Cedar Mundi Ventures | Beirut, Beyrouth, Lebanon |
| Cipio Partners | Luxembourg, Luxembourg |
| Employee Stock Option Fund (ESO Fund) | California, San Mateo, United States |
| Ground 1 Ventures | England, London, United Kingdom |
| Hatou Jituan | - |
| Hengjian Holding | China, Guangdong Province, Huizhou |
| Immortalana | California, Los Angeles, United States |
| Makower Family Trust | California, San Francisco, United States |
| Mid Atlantic Bio Angels | New York, New York, United States |
| Moody Foundation | Galveston, Texas, United States |
| Sciety | Stockholm, Stockholm County, Sweden |
| Shanghai Baoding Investment Management | China, Shanghai |
| Tako Ventures | California, San Francisco, United States |
| Technion Research & Development Foundation | Hefa, Hefa, Israel |
| The Sapling Fund | Columbus, Ohio, United States |
| Urca Angels | Brazil, São Paulo, Sao Paulo |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Insyce | $23M | 04 Jan 2023 | Nanjing, Jiangsu, China | ||
Insyce | 18 Nov 2022 | Nanjing, Jiangsu, China | |||
Insyce | 08 Feb 2022 | Nanjing, Jiangsu, China | |||
Carmine Therapeutics | $3M | 29 Aug 2019 | Cambridge, Massachusetts, United States | ||
Nanoview Biosciences | $5M | 04 May 2017 | Boston, Massachusetts, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Insyce | $23M | 04 Jan 2023 | Nanjing, Jiangsu, China | ||
Insyce | 18 Nov 2022 | Nanjing, Jiangsu, China | |||
Insyce | 08 Feb 2022 | Nanjing, Jiangsu, China | |||
Carmine Therapeutics | $3M | 29 Aug 2019 | Cambridge, Massachusetts, United States | ||
Nanoview Biosciences | $5M | 04 May 2017 | Boston, Massachusetts, United States |
